Cargando…

Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy.

Northern hybridization analyses of the oestrogen-inducible mRNAs pLIV1 and pS2 were compared with oestrogen receptor (ER) immunocytochemistry assessments in 40 untreated primary or early recurrent breast tumours. Significant associations were observed between pLIV1/ER (P < 0.03), pS2/ER (P < 0...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClelland, R. A., Manning, D. L., Gee, J. M., Willsher, P., Robertson, J. F., Ellis, I. O., Blamey, R. W., Nicholson, R. I.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150074/ https://www.ncbi.nlm.nih.gov/pubmed/9635843

Ejemplares similares

Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.
por: Sharma, A. K., et al.
Publicado: (1994)

Oestrogen receptors in primary breast cancer.
por: Williams, M. R., et al.
Publicado: (1985)

Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
por: Robertson, J. F., et al.
Publicado: (1992)

Microarray studies reveal novel genes associated with endocrine resistance in breast cancer
por: Burmi, RS, et al.
Publicado: (2006)

Oestrogen-receptor status and sites of metastasis in breast cancer.
por: Campbell, F. C., et al.
Publicado: (1981)

Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer
por: Nicholson, RI, et al.
Publicado: (2000)

Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.
por: Williams, M. R., et al.
Publicado: (1987)

Tumour epithelial cellularity and quantitative oestrogen receptor values in primary breast cancer.
por: Mumford, C. J., et al.
Publicado: (1983)

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
por: Stone, Andrew, et al.
Publicado: (2015)

p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
por: Poller, D. N., et al.
Publicado: (1992)

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
por: Hutcheson, Iain R, et al.
Publicado: (2011)

Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.
por: Roberts, M. M., et al.
Publicado: (1978)

Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer
por: Stone, Andrew, et al.
Publicado: (2012)

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells
por: Borley, Annabel C, et al.
Publicado: (2008)

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
por: Archer, S. G., et al.
Publicado: (1995)

Zinc and Cancer: Implications for LIV-1 in Breast Cancer
por: Grattan, Bruce J., et al.
Publicado: (2012)

Adobe GoLiv
por: Adobe Press
Publicado: (2004)

erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines
por: Knowlden, Janice M, et al.
Publicado: (2011)

Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells
por: Knowlden, JM, et al.
Publicado: (2010)

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.
por: Howell, A., et al.
Publicado: (1996)

Relationship between oestrogen-receptor content and histological grade in human primary breast tumours.
por: Maynard, P. V., et al.
Publicado: (1978)

Oestrogenic Endocrine Disruptors in the Placenta and the Fetus
por: Tang, Zi-Run, et al.
Publicado: (2020)

Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.
por: Leake, R. E., et al.
Publicado: (1981)

Extreme growth factor signalling can promote oestrogen receptor-α loss: therapeutic implications in breast cancer
por: Gee, Julia MW, et al.
Publicado: (2004)

Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
por: Poller, D. N., et al.
Publicado: (1993)

Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985)

Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.
por: Henry, J. A., et al.
Publicado: (1990)

Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor
por: Bensmail, A, et al.
Publicado: (2008)

Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
por: Anderson, E. D., et al.
Publicado: (1989)

In memoriam: Liv Hatle 1936–2023, pioneering echocardiologist
por: Fraser, Alan G, et al.
Publicado: (2023)

Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity
por: Stone, A, et al.
Publicado: (2008)

Measurement of oestrogen receptor mRNA levels in human breast tumours.
por: Henry, J. A., et al.
Publicado: (1988)

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
por: Bouzubar, N., et al.
Publicado: (1989)

Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival
por: McKeen, H, et al.
Publicado: (2008)

Do classical oestrogen markers predict for clinical response to endocrine therapy?
por: Miller, William R
Publicado: (2007)

Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor.
por: Piva, R., et al.
Publicado: (1990)

Oestrogen receptor: a stable phenotype in breast cancer.
por: Robertson, J. F.
Publicado: (1996)

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990)

Breast cancer: a comparison of response to endocrine therapy and oestrogen excretion patterns including unusual metabolites.
por: Castagnetta, L., et al.
Publicado: (1981)

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
por: Osborne, C K, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_rs43d9jis3d3gugm0fanbqv3tp